InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
17 hedge funds and large institutions have $1.17M invested in InVivo Therapeutics Holdings Corp in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 16 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
32% less funds holding
Funds holding: 25 → 17 (-8)
46% less capital invested
Capital invested by funds: $2.17M → $1.17M (-$997K)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.24M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$1.15M |
| 3 |
Renaissance Technologies
New York
|
+$861K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$571K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$401K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$143K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$123K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$115K |
| 4 |
WF
Welch & Forbes
Boston,
Massachusetts
|
-$52K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$40K |
NVIV Hedge Fund Activity: Q2 2018 in Review
17 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2018, worth a combined $1.17M — down 46% from $2.17M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of NVIV and 8 opened new positions — a net loss of 8 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.24M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $143K sold.
- 17 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2018, down from 25 in Q1 2018.
- Funds reported $1.17M of InVivo Therapeutics Holdings Corp stock for Q2 2018, down 46% quarter-over-quarter.
- 8 funds opened new InVivo Therapeutics Holdings Corp positions in Q2 2018 and 16 closed out, a net change of -8 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q2 2018 was Sabby Management, an estimated $1.24M added.
- The largest InVivo Therapeutics Holdings Corp seller in Q2 2018 was Susquehanna International Group, an estimated $143K sold.
Based on aggregated 13F filings for Q2 2018.